Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

Recruiting

Phase 2

Fecal Microbiome TransplantationFecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

Sponsor:

City of Hope Medical Center

Code:

NCT07042438

Conditions

Recurrent Diffuse Large B-Cell Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Refractory Diffuse Large B-Cell Lymphoma

Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Axicabtagene Ciloleucel

Biospecimen Collection

Chemotherapy

Fecal Microbiota Transplantation

Leukapheresis

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-30. This information was provided to ClinicalTrials.gov by City of Hope Medical Center on 2026-03-05.